我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
40
8 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1915
进行中（未招募）
1
2.5%
已完成
13
32.5%
Enrolling By Invitation
尚未招募
6
15.0%
招募中
2
5.0%
Unknown
17
42.5%
暂无批准数据
- SK Biopharmaceuticals has officially launched its innovative epilepsy drug Cenobamate in China, with first prescriptions beginning at major hub hospitals across the country. - The drug received approval from China's National Medical Products Administration in December 2024 for treating focal-onset seizures in adults, entering full commercialization three months later. - Cenobamate aims to shift epilepsy treatment goals from "seizure control" to "seizure freedom" in China, representing a significant advancement in therapeutic approach. - The company plans to accelerate expansion into Northeast Asian markets including Korea and Japan through strategic partnerships with regional collaborators.
